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Abstract
Each year millions of newborns are part of a newborn disease-screening program in which, after initial screening, the
newborn dried blood spot (NDBS) samples can be stored and used as a population-based research resource. However, very
little knowledge exists about how these samples are used for secondary purposes. Our objective is to estimate and describe
the usage of a NDBS-based national population biobank for secondary research purposes. We therefore conducted a scoping
study with a literature search for all published articles using samples from the Danish Newborn Screening Biobank. Our
main inclusion criteria were that the articles had to have actively used and analyzed one or more of the Danish NDBS
samples for a purpose beyond the primary screening. Our search led to a ﬁnal 104 articles, which were coded for three main
purposes: (1) how many samples were used in each article, (2) the ﬁeld of their research, and (3) information on consent and
ethics approval as research. From our analysis, we present two main ﬁndings: an estimated use of up to 37.5% of all samples
in the newborn screening biobank have been part of published research, and a shift in the research areas from methodological
and metabolic studies to studies concerning mental illness. This paper provides new insights into the use of a national
biobank, and we hope that the results will contribute to the discussions on the use of biological samples for research
purposes, and also inspire a greater transparency in the future use of NDBS samples.
Introduction
Newborn dried blood spots (NDBS) are routinely stored and
used for research purposes. Every year, millions of new-
borns worldwide are a part of a newborn screening program,
where a few drops of blood from the baby’s heel are col-
lected on a ﬁlter paper card. After the primary screening
program, the NDBS can be stored in a freezer at the Danish
Newborn Screening Biobank, under the Danish Statens
Serum Institute and used for secondary purposes.
With this paper, our aim is to move beyond the primary
screening purpose and elucidate how often and for which
objectives the Danish NDBS samples are used for second-
ary purposes. The aims of our study are (1) to estimate how
often the Danish NDBS samples are used for secondary
purposes and what the probability is of a person’s sample
being used, and (2) to describe what kind of research the
Danish NDBS samples are used for. From contact with the
Danish Newborn Screening Biobank, we understood that no
metadata exists on how many samples had been used for
secondary purposes; nor for what kind of research the
Danish NDBS samples had been used. To answer these
questions, we therefore conducted a scoping study [1, 2] of
all articles using the Danish NDBS samples.
We argue for the importance of reaching, as accurately as
possible, an estimate of the use of samples in the Danish
Newborn Screening Biobank from four main perspectives:
First, the debates around the use of NDBS samples has
often been concerning consent policies [3–6]. Here, it is
crucial to understand the practical implications of seeking
and giving consent to research based on the NDBS sample,
yet no information regarding this is available. Without any
numbers, these discussions are based on uncertain
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assumptions. Second, knowing what kind of research is
conducted using the NDBS samples is essential to under-
stand both what the population might (unknowingly) be
participating in, and what kind of research is made possible
with the NDBS samples. Third, international debate has
revolved around the relationship between gathering, storing,
and using samples in biobanks—in particular, the impor-
tance of exploiting the full potential of the biobanks by
sharing and using the samples [7]. Again, empirical insights
to the actual use of biobanks would straighten these dis-
cussions. Information as to the relationship between the
storage and use of samples from the Danish Newborn
Screening Biobank will provide valid input in discussion on
the use of biobank material and will serve as input to the
debate of informed consent. And fourth, increased knowl-
edge about when and how the Danish NDSB samples are
used for research can help increase the level of under-
standing of why the NDBS samples are collected and stored
for the public [8].
The use of NDBS samples for research purposes has also
been a topic for international controversy. Most famous is
the case from Texas where the dispute over the retention
and use of the samples without parental knowledge or
consent led to the destruction of over ﬁve million NDBS
samples [9].
In Denmark, newborn screening was implemented
nationally in 1982 [10], and since then an average of 62,000
newborns are annually a part of the Danish newborn
screening program. Although the screening program is
legally voluntary, it might not always be perceived as such
by the parents. The blood spots are sent from the hospitals
to the national Statens Serum Institute [10] where they are
currently screened for 17 diseases [11] and subsequently
stored indeﬁnitely in the Danish Newborn Screening Bio-
bank at the institute [12]. The samples are stored for three
reasons: for the use of the child and the family, in case of
further diagnostics or for identiﬁcation purposes; for use in
quality assurance and development of new analysis meth-
ods; and ﬁnally, the biobank also serves as a national
resource for research purposes [13]. By Danish law, the
samples can legally be stored and later used without explicit
informed consent [14]; accordingly, problems of selection
bias are avoided. Consent for the storage and subsequent
use of the samples is embedded in allowing the sample to be
taken. The policies enabling this kind of population-based
data sourcing and usage are not unique in the Danish setting
but are in many ways an example of Denmark as a “research
radical country” [15]. In practice, consenting to having your
child screened for diseases is also a (tacit) consent both to
having your child’s sample stored and also to the sample
being used for secondary purposes [16]. Acquiring access to
the NDBS samples for researchers is a four-step process.
First, the project must be approved by a Research Ethics
Committee and the Danish Data Protection Agency. Sec-
ond, the project may apply via Scientiﬁc Services; the joint
Danish port of access to biological material and data under
the Danish Health Data Authority. The application will then
be forwarded to the Coordinating Centre at the Danish
National Biobank, which will process the case. Third, all
applications received are processed and accessed by the
Scientiﬁc Board of the Danish National Biobank. And
ﬁnally, if the three steps above are all approved and the
terms of the hand-out are agreed upon, the samples are then
retrieved and handed out [17].
Opting out of the research participation by signing up in
the “use-of-tissue-register” [vævsanvendelsesregisteret]
[18] is a possibility in Denmark; however, fewer than 500
people (from a population of ~ 5.7 million) are currently in
the “use-of-tissue-register” [19]. It is unknown whether this
is because people genuinely wish to participate in research
based on their tissue sample, or because they are simply
unaware of the possible participation and the opt-out option
[20]. Moreover, the Danish NDBS samples can be linked to
register data and to health records through the Central
Person Register (known as CPR) number, a unique 10-digit
civil registration number assigned to all the country’s resi-
dents [21, 22]. Similar to other Scandinavian countries, this
creates a unique setting for epidemiologic research. The
continuing national sampling and storage of NDBS from the
whole of the Danish population thus makes a valuable
resource for existing and future genomic research projects.
Material and methods
In this scoping study [1, 2], we identiﬁed relevant studies by
searching for articles using the Danish NDBS samples. The
intention was originally to analyze how often these samples
were used for research purposes. However, differentiating
between what can be categorized as research and what is not
research appeared less meaningful than we ﬁrst expected. In
this article, we therefore consider all purposes that are not
the primary screening to be secondary purposes and will
discuss their relation to research. Therefore, our main
inclusion criteria were that the published articles had to
have actively used and analyzed one or more of the Danish
NDBS samples for a purpose beyond the primary screening.
We searched for articles in Scopus and PubMed MED-
LINE as the two largest databases covering medicine and
health-related research ﬁelds [23, 24]. We made a ﬁnal
search in both databases on 01 January 2018.
We combined the following terms in our search:
("Newborn" OR "Infant" OR "neonatal”) AND
("Bloodspot*" OR "Blood spot*" OR "NDBS" OR "DBS"
OR "DBSS" OR "PKU" OR "Guthrie card") AND ("Den-
mark" OR "Danish").
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In addition, a search for articles directly referring to the
Danish Newborn Screening Biobank was undertaken with
the following search string:
(“Danish Newborn Screening Biobank”) OR (“DNSB”)
Our initial search resulted in 372 published articles.
Removing duplicates left 291 individual articles. These we
screened on abstract for relevance. Exclusion criteria based
on abstract mainly included: reviews; studies on attitudes;
other use of the abbreviations in our search; and articles
from before 1982. The remaining 234 articles were screened
on full text for eligibility. The main exclusion criteria were
as follows: if the articles did not actively use Danish NDBS
samples, but were, for the majority, studies with non-Danish
samples; legal, social, policy, ethical, or future perspectives
of NDBS samples and biobanking; studies based on other
neonatal blood tests; or studies on phenylketonuria without
the use of NDBS samples. This left 102 articles. All of these
articles were screened on references for additional articles
using Danish NDBS samples. This resulted in another two
articles being included in our study. Finally, this gave us
104 published articles (please full list of articles in
the supplementary material). The ﬂow is presented in Fig. 1.
All of the ﬁnal 104 eligible articles were combined in one
Excel data set for later analysis in R. Nvivo 11 Pro was used
for all coding of the articles. We coded all 104 articles for
the following three main purposes: (1) how many samples
were used in each article, (2) the ﬁeld of their research,
and (3) information on consent and ethics approval for
research.
The number of samples used was recorded manually by
detecting and coding all the samples in each of the 104
articles. We searched for the number of samples, whether
the samples were a clinical case, cases (patients), controls,
cohort, or a random sampling. In order to give an estimate
of how many Danish NDBS samples have been used for
research purposes in total, we sought to eliminate counting
the reuse of samples. Approximately 80,000 Danish NDBS
samples were included in a large research project, iPSYCH,
a Danish population-based case–cohort, aimed at unraveling
the genetic and environmental structure of ﬁve mental dis-
orders (autism, ADHD, schizophrenia, bipolar disorder, and
depression) [25], resulting in multiple published articles. All
samples in articles from the iPSYCH project were therefore
counted within this total. Further, some samples were used
for more than one article. In cases where this was stated, the
samples were only counted in the ﬁrst article.
Results
Estimations of use of the Danish NDBS samples
The ﬁrst article using the Danish NDBS samples is from
1991 and the latest is from November 2017. There is an
Fig. 1 Prisma Flow on search
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increase in the number of articles throughout the period,
which is not surprising considering the expansion of pos-
sibilities of using the NDBS samples. With the increase in
articles there is also an increase in the number of samples
used, and the probability for one person’s sample having
been used therefore also increases over time. We have
estimated the maximum proportion of NDBS samples that
have been used for secondary purposes in published
manuscripts by extracting the number of samples used in all
articles surveyed divided by the cumulative number of
newborns since the beginning of the newborn screening
program. The 104 articles had an estimated total use of
794,157 individual samples. The State Serum Institute was
not able to provide the exact number of samples in their
biobank, but based on earlier literature, the biobank holds
samples from ~ 95% of all births [19, 25]. The number of
samples in the biobank from 1982–2017, therefore came to
2,120,163 at the time of our analysis. This would suggest
that an estimated average of 37.5% of the samples in the
Danish newborn screening biobank have therefore been
used for secondary purposes, the research outcomes of
which were published in an academic journal by 1 January
2018. As we cannot be certain that there are no duplicate
individuals among the 794,157 samples, the estimate pro-
vides an upper limit for the proportion of individuals in the
Danish Newborn Screening Biobank who have had their
samples used for research.
The estimates in Fig. 2 are based on the number of
samples found to have been used each year, as recorded in
the published articles. The estimates presented here account
for the use to date based on published research articles. The
true percentage of individuals in the Danish newborn
screening biobank who have been used for secondary
research purposes could be much higher as we do not have
any information on usage that is still in the publication
pipeline or individuals who have been used for research that
is not published. Estimations of future use are somewhat
unpredictable. We know that the number of samples
entering the biobank is closely linked to the number of
births. However, the number of samples used for research
purposes is dependent on a number of unpredictable factors,
such as the interest in these samples compared with others,
possibilities for funding for research projects using the
NDBS samples, and policies concerning the use of Danish
NDBS samples.
Of the 104 articles, 75 identify as research projects and
therefore have an approval from the relevant research ethics
committee. Eleven articles declare that the project does not
constitute a health-related research project but is considered
a developmental project for the Newborn Screening Pro-
gram instead and therefore does not require a separate
approval from the research ethics committee. And 18 of the
articles do not clearly state anything about research or
approvals from an ethics committee. Finally, only 16 of the
articles clearly state having consent from all of their parti-
cipants. However, it is not always precisely stated how
consent is understood, nor how it was obtained.
Research ﬁelds
The Danish NDBS samples have been used to facilitate
studies of a variety of ﬁelds. By categorizing each article,
we found that the rates at which the NDBS samples are
being utilized for secondary research publication have
varied substantially over time and research ﬁeld, as shown
in Fig. 3.
Approximately one-third (n= 36) of the articles study
the methodological possibilities of NDBS samples. Of
those, 14 articles study the methodological approach to
Fig. 2 Estimated proportion of NDBS samples used for secondary
research as a function of year (the black dots). The points indicate the
cumulative prevalence, whereas the solid curve shows a smoothed
trend line
Fig. 3 All use of Danish NDBS samples over time. Each bubble shows
the number of NDBS articles per year, the color distribution indicates
the relative contributions of the articles to the various research ﬁelds,
whereas the bubble sizes indicate the total number of samples involved
in the articles from that year. The black curve is a smoothed trend
curve of article frequencies
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using NDBS samples for a speciﬁc diagnosis, and 13 of the
articles study methods without targeting a speciﬁc disease.
Besides the methodological studies, the largest research
ﬁeld in the articles is mental illness. Twenty-three out of the
104 articles, and an estimated 91,162 individual samples,
have been used to study either a speciﬁc exposure with
mental illness as outcome, or the possible genetic compo-
sition found in children or adults with a mental illness.
Other larger research ﬁelds include diseases related to the
metabolism (15 articles), type 1 diabetes (9 articles), and
toxoplasma (8 articles). The ﬁelds of metabolism and tox-
oplasma are a current or former part of the primary newborn
screening program; however, we have only included articles
that study these ﬁelds in a setting secondary to the primary
screening.
Of the 794,157 used samples, a relatively large number,
84,299, are from participants with a diagnosis. The possi-
bility of participating in research therefore is higher for
people with a diagnosis (which often only comes about
when individuals reach childhood or adulthood). For
instance, ~ 12,000 people born after 1982 are diagnosed
with type 1 diabetes (calculation based on [26]). We found
that 7509 individual NDBS samples from people with a
type 1 diabetes diagnosis have been used for research pur-
poses. This would suggest that an estimated 62% of all
samples from patients with type 1 diabetes have been used
for research purposes, an increase of 25 percentage points
compared with the overall proportion found for the indivi-
duals with a Danish NDBS samples.
As shown in Fig. 3, the numbers of samples used vary
widely from year to year. As for research ﬁelds, there is an
early interest in toxoplasma, which was a part of the Danish
newborn screening program from 1999 to 2007 [11]. The
later years have shown a marked increase in two main areas:
type 1 diabetes, and more especially in mental illness. This
could suggest a shift in the kind of research the samples are
used for: moving from objectives closely related to the
primary purpose, to objectives completely unrelated to the
primary purpose but the research ﬁelds shown in Fig. 3 are
purely descriptive and do not provide any indication as to
which research ﬁelds will be the main in the future.
For all of the 104 articles, the top three most productive
authors are Hougaard, D. (ﬁrst author or co-author of 53
articles), Hollegaard, M. (ﬁrst author or co-author of 29
articles), and Nørgaard-Pedersen, B. (ﬁrst author or co-
author of 27 articles). All three authors are current or former
employees at the State Serum Institute.
Discussion
Denmark is known as the “epidemiologist’s dream” [27]
because of its widespread register structure and vast data
collection [28]. A national biobank containing samples from
a majority of the population since 1982 hugely expands the
opportunities for population-wide research using both reg-
isters and genetic information. However, information about
the usage of this resource is non-existent for both
researchers and for the public, who contributed to it. This
paper is the ﬁrst attempt to elucidate how this national
biobank has been utilized.
From the analysis of all articles using the Danish NDBS
samples, our ﬁndings indicate that just under 40% of the
samples in the Newborn Screening Biobank have been used
for secondary purposes. Since this is, to our knowledge, the
ﬁrst ever actual estimate of the secondary use of a national
biobank, it is not possible to compare it with the use of other
biobanks. Furthermore, the earliest article using the Danish
NDBS samples is from 1991, almost 10 years after the ﬁrst
sample was stored. This could indicate that the storing of
the samples was initially not with a research purpose in
mind.
Any research project using the samples must prove that
the project has been approved by the Danish Data Protec-
tion Agency, and by the Scientiﬁc Ethical Committee sys-
tem, as well as by the Steering Committee for Scientiﬁc Use
of the Danish Newborn Screening Biobank [12]. According
to Danish law [14], all health-related research projects
require informed consent from each participant. However,
because using the Danish NDBS samples for research
purposes is considered to be register-based research [29],
the National Committee on Health Research Ethics can
waive the requirement for consent, if the research project
does not imply health-related risks, and if the research
project does not in other ways burden the participant. An
exception can also be made if it would be impossible or
disproportionately difﬁcult to acquire consent [14]. As both
are often the case for research projects using the Danish
NDBS samples, projects are often permitted by The
National Committee on Health Research Ethics to be
implemented without consent. However, in the light of the
practical implications for consent, our ﬁndings suggest that
just under 40% of the population born in Denmark after
1982 have had their sample used for purposes beyond the
primary screening. If researchers had to actively seek con-
sent for the use of each sample for secondary purposes, it
would have implied getting consent from the estimated
794,157 individuals in the period from 1991 to 2017. It is
unknown how many people would not participate in
research based on their NDBS samples, if they had to give
consent for each project. However, one of the research
projects using almost 100,000 NDBS samples incorporated
consent when the samples were taken [30]. Here, only 179
(0.18%) declined participation. In research projects using
fresh NDBS samples, this could prove a way to get explicit
consent for the speciﬁc study. However, this solution will
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not be possible for samples already stored in the biobank. In
these cases, obtaining consent could prove much more
problematic. Moreover, people who have a diagnosis of
interest for researchers using the Danish NDBS samples,
have a higher probability of having their sample used, as
exempliﬁed with type 1 diabetes. Having a diagnosis of
interest would therefore imply having to give consent more
often.
Our ﬁndings further indicate a shift in the type of
research carried out using the Danish NDBS samples. What
was in the beginning, a resource for research projects clo-
sely related to the primary purpose, is now also a resource
for research with objectives not in any way related to the
primary purpose. This shift could represent a change in
how the researchers perceive the Danish Newborn Screen-
ing Biobank as a resource, and it could also become
crucial for how the secondary use of NDBS samples is
perceived by the parents of the newborns and by the public
at large.
One ﬁeld particularly worth discussing is the usage of
NDBS samples for studying mental illness. Twenty-three of
the 104 articles use the Danish NDBS samples to study
mental illness, which shows a descriptive trend in how the
samples have been used until now. These studies further
show how important a resource the NDBS biobank is. It is
well established that it can be difﬁcult to get people to
participate in research on mental illness [31] and using the
NDBS samples linked with information about mental illness
must be considered a valuable resource for increasing
knowledge on mental illness and possible treatment. These
studies are therefore often done without explicit consent
from the participants. This serves as an example of the
complex situation of using the NDBS samples without
consent: it facilitates vital research that could otherwise not
be done, and simultaneously requires people to participate
in research they might not wish to participate in.
Even though the majority of the articles included are
deﬁned as research, some of the included studies could be
considered “non-research”. For instance, some of the
methodological studies presented in the articles are con-
sidered a developmental project for the Newborn Screening
Program. However, none of the samples were gathered with
the primary purpose of being a part of a methodological
study. Moreover, not all methodological articles are con-
sidered a developmental project for the Newborn Screening
Program. For instance, an article from 2009 by Hollegaard
et al. [32] studying “High-Throughput Genotyping on
Archived Dried Blood Spot Samples” is approved by the
Danish Regional Ethics Committee (as a research project)
whereas Poulsen et al. from 2015 [33] studying “High-
Quality Exome Sequencing of Whole Genome Ampliﬁed
Neonatal Dried Blood Spot DNA” is not considered
research. So, differentiating between what is research and
what is not, seems challenging for the researchers them-
selves. Likewise, the Newborn Screening Biobank has
earlier stated how projects using biobank material should be
considered “research projects” [12]. Finally, the Danish
public would probably in many cases not recognize the
difference between having their sample used for whole-
genome ampliﬁcation of DNA [34] as a part of a develop-
mental project as opposed to a research study of levels of
vitamin D [35]. This further indicates that the division
between what is research and what is not, might not be
clear-cut, neither in practice nor in theory.
We also found that the main users of the NSBS samples
are employed at the State Serum Institute. This could
indicate that the knowledge of the availability of the sam-
ples as a resource is, for the general Danish research com-
munity, rather limited; or that the procedures for acquiring
access to the samples are complicated; or that research
involving the Danish NDBS samples is often done in col-
laboration with the specialized researchers at the State
Serum Institute. In any case, it could be considered pro-
blematic that samples belonging to the whole population are
most often only used by those controlling the very biobank
that holds the samples.
Returning to our own study, several factors could inﬂu-
ence how close our estimates are to the actual number of
Danish NDBS samples used for research purposes. First of
all, our search led us to the 104 articles. We are aware that
some articles using the Danish NDBS samples might not
appear from this search, if they do not state that their results
are based on these samples. Not clearly stating where one’s
data are originated does in itself bring about challenges, and
much work is being done in order to facilitate proper cita-
tion of bio resources [36]. We have tried to minimize the
risk of unfound articles by searching two different databases
and by checking the references of each found article. Sec-
ond, it is possible that samples have been used for research
purposes, but that this use has not been reported in aca-
demic articles. The extent of this usage is unknown.
Moreover, we can only make our estimates based on the
number of samples reported in the articles, which might not
always equal the actual number of samples withdrawn for
each project. Finally, we have tried to identify how many
individual samples have been used, though it is possible that
a sample is utilized for more than one research project,
without this being stated in the articles. However, bearing in
mind that there should always be a part of the NDBS sample
left for the child, the probability of multiple usage of the
same sample decreases. With that said, we believe our
estimate to be solidly-based in the circumstances. It is, to
our knowledge, the ﬁrst and only estimate of the actual
usage of a national biobank, and therefore the best available
estimate of the use of NDBS samples for secondary
purposes.
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Conclusions
With this paper, we have presented new insights into the use
of a national biobank. From our analysis we present two
main ﬁndings. First, there has been an estimated use of
almost 800,000 Danish NDBS samples, corresponding to ~
37.5% of all samples in the biobank based on published
manuscripts alone. Further, we clariﬁed how these samples
have been used principally for methodological studies or
studies concerning mental illness, and how there has been a
shift away from using the samples for studies closely related
to the primary purpose, toward studies not related to the
primary purposes. The only way for us to acquire this
knowledge was to go through all articles that report use of
the samples, as very little information was otherwise
accessible. We believe that the information presented in this
paper is important not just as an empirical ﬁnding for the
discussions concerning the use of biological samples for
secondary purposes, but also as information for the general
public. As the samples are taken from almost all children
born in Denmark, it is a national biobank, and the infor-
mation derived from the samples should arguably therefore
also belong to the nation. If knowledge about the use of the
Danish NDBS samples is not shared, we risk creating a
sense of uncertainty and possibly even mistrust and thereby
risk that parents will in future refuse to have their child’s
sample stored. The need for transparency for the data sub-
ject as likewise an essential notion of the European Union’s
general data protection regulation (REF) [37], which
increases the need for these considerations for the Danish
Newborn Screening biobank and biobanks in general. We
hope that the results presented in this paper will contribute
to discussions around the use of biological samples for
research purposes, and also that we will have led the way
towards a greater transparency in the future use of NDBS
samples and biobank samples in general.
Acknowledgements This project has received funding from the Eur-
opean Research Council (ERC) under the European Union’s Horizon
2020 research and innovation program (grant agreement number
682110).
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Arksey H, O’Malley L. Scoping studies: towards a methodolo-
gical framework. Int J Res Mathedol. 2005;8:19–32.
2. Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing
the methodology. Implement Sci. 2010;5:69.
3. Hayeems RZ, Miller FA, Barg C, et al. Using newborn screening
bloodspots for research: public preferences for policy options.
Pediatrics. 2016;137:e20154143.
4. Kharaboyan L, Avard D, Knoppers BM. Storing newborn blood
spots: modern controversies. J Law Med Ethics. 2004;32:741–8.
5. Douglas CM, van El CG, Faulkner A, Cornel MC. Governing
biological material at the intersection of care and research: the use
of dried blood spots for biobanking. Croat Med J. 2012;53:390–7.
6. Botkin JR, Goldenberg AJ, Rothwell E, Andeson RA, Lewis MH.
Retention and research use of residual newborn screening
bloodspots. Pediatrics. 2013;131:120–7.
7. Colledge F, Elger B, Howard HC. A review of the barriers to
sharing in biobanking. Biopreserv Biobank. 2013;11:339–46.
8. Botkin JR, Rothwell E, Anderson RA, et al. What parents want to
know about the storage and use of residual newborn bloodspots.
Am J Med Genet A. 2014;164:2739–44.
9. Waldo A. The Texas newborn bloodspot saga has reached a sad—
and preventable—conclusion. Genomics Law Report. 16 March
2010; 1–45.
10. Nørgaard‐Pedersen B, Simonsen H. Biological specimen banks in
neonatal screening. Acta Paediatr. 1999;88:106–9.
11. Statens Serum Insitut. Sygdomme som indgår i screeningen.
(Diseases in the screening programme) [Internet]. 2017 [Cited
Novemer 2017]. Available from: https://www.ssi.dk/Diagnostik/
Center for NeonatalScreening/Sygdomme som indgaer i screen-
ingen.aspx.
12. Nørgaard-Pedersen B, Hougaard DM. Storage policies and use of
the Danish Newborn Screening Biobank. J Inherit Metab Dis.
2007;30:530–6.
13. Statens Serum Insitut. To parents: blood samples from newborn
babies, 13th edn. Copenhagen: Statens Serum Institut; 2017.
14. Folketinget. Bekendtgørelse af lov om videnskabsetisk behandling
af sundhedsvidenskabelige forskningsprojekter. (The Danish
Parliament. Order of law on scientiﬁc treatment of health scientiﬁc
research projects). Copenhagen: Folketinget; 2017.
15. Hoeyer K. Denmark at a crossroad? Intensiﬁed Data Sourcing in a
Research Radical Country. In B Mittelstad, L Floridi, editors. The
ethics of biomedical big data, Springer International Publishing:
Switzerland, 2016. p. 73–93.
16. Winkler BB. Retlige rammer for registerforskning med biologisk
materiale. (Legal framework for registerbased research with bio-
logical material). Copenhagen: Ministeriet for sundhed og Fore-
byggelse; 2014.
17. Danmarks Nationale Biobank. Guidelines on access to biological
material and data from The Danish National Biobank. Copenha-
gen: Statens Serum Institut; 2016.
18. Sundhedsdatastyrelsen (2017). Til- og framelding til Vævsan-
vendelsesregisteret. (Enrolment and withdrawel fom the use-of-
tissue-register). 2017. Available from: https://sundhedsdata
styrelsen.dk/var.
19. Hartlev M. Genomic databases and biobanks in denmark. J Law
Med Ethics. 2015;43:743–53.
20. Mandrup M, Hansen MB. Forskere: For få borgere kender
til systemet bag biobankerne. (Researchers: Too few citizens
Newborn dried blood spot samples in Denmark: the hidden ﬁgures of secondary use and research. . . 209
know about the system behind biobanks). Ingeniøren April 1st,
2012.
21. Mortensen PB, Gøtzsche H, Bøcker Pedersen C, Østrup Møller J.
The Danish Civil Registration System: a cohort of eight million
persons. Dan Med Bull. 2006;53:441–9.
22. Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H.
Introduction to Danish (nationwide) registers on health and social
issues: Structure, access, legislation, and archiving. Scand J Public
Health. 2011;39:12–16.
23. Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of
PubMed, Scopus, web of science, and Google scholar: strengths
and weaknesses. FASEB J. 2008;22:338–42.
24. Jacso P. As we may search—comparison of major features of the
Web of Science, Scopus, and Google Scholar citation-based and
citation-enhanced databases. Curr Sci. 2005;89:1537–47.
25. Pedersen CB, Bybjerg-Grauholm J, Pedersen MG, et al. The
iPSYCH2012 case–cohort sample: new directions for unravelling
genetic and environmental architectures of severe mental dis-
orders. Mol Psychiatry. 2017;23:6–14.
26. Steno Diabetes Center Copenhagen. Diabetes i tal (Diabetes in
numbers). 2017. Available from: https://www.sdcc.dk/livet-med-
diabetes/om-diabetes/Sider/Diabetes-i-tal.aspx.
27. Frank L. The epidemiologist’s dream: Denmark. Science.
2003;301:163
28. Thygesen LC, Ersbøll AK. When the entire population is the
sample: strengths and limitations in register-based epidemiology.
Eur J Epidemiol. 2014;29:551–8.
29. Datatilsynet. Datatilsynets årsberetning 2000. The Danish Data
Protection Agencys annual report 2000. Copenhagen; Datatilsynet
Denmark, 2001.
30. Lebech M, Andersen O, Christensen NC, et al. Feasibility of
neonatal screening for toxoplasma infection in the absence of
prenatal treatment. Lancet. 1999;353:1834–7.
31. Woodall A, Morgan C, Sloan C, Howard L. Barriers to partici-
pation in mental health research: are there speciﬁc gender, ethni-
city and age related barriers? BMC Psychiatry. 2010;10:103.
32. Hollegaard MV, Grove J, Thorsen P, Nørgaard-Pedersen B,
Hougaard DM. High-throughput genotyping on archived dried
blood spot samples. Genet Test Mol Biomark. 2009;13:173–9.
33. Poulsen JB, Lescai F, Grove J, et al. High-quality exome
sequencing of whole-genome ampliﬁed neonatal dried blood spot
DNA. PLoS ONE. 2016;11:e0153253.
34. Bækvad-Hansen M, Bybjerg-Grauholm J, Poulsen JB, Hansen
CS, Hougaard DM, Hollegaard MV. Evaluation of whole genome
ampliﬁed DNA to decrease material expenditure and increase
quality. Mol Genet Metab Rep. 2017;11:36–45.
35. Nielsen NM, Munger KL, Koch-Henriksen N, et al. Neonatal
vitamin D status and risk of multiple sclerosis A population-based
case-control study. Neurology. 2017;88:44–51.
36. Mabile L, De Castro P, Bravo E, et al. Towards new tools for
bioresource use and sharing. Inform Serv Use. 2016;36:133–46.
37. European Union. Regulation (EU) 2016/679 of the European
Parliament and of the Council of 27 April 2016. OJEU. 2016;
L119/1.
210 F. Nordfalk, C. T. Ekstrøm
